• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LY264826与其他糖肽类抗生素和达托霉素的体外活性比较。

In vitro activity of LY264826 compared to other glycopeptides and daptomycin.

作者信息

Chin N X, Neu H C

机构信息

Department of Medicine, College of Physicians and Surgeons, New York, New York.

出版信息

Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181-4. doi: 10.1016/0732-8893(91)90056-l.

DOI:10.1016/0732-8893(91)90056-l
PMID:1651826
Abstract

LY264826 a new naturally occurring glycopeptide inhibited 90% of methicillin-susceptible and -resistant Staphylococcus aureus at 1 micrograms/ml. LY264826 had similar activity against methicillin-susceptible and -resistant coagulase-negative staphylococci. The LY264826 MIC90 for Streptococcus pyogenes was 0.25 microgram/ml, twofold more active than vancomycin and twofold less active than teicoplanin. LY264826 was eightfold more active than vancomycin and twofold more active than teicoplanin against enterococci. LY264826 inhibited Streptococcus pneumoniae at 0.25 microgram/ml and Listeria monocytogenes at 0.5 microgram/ml. Clostridium were inhibited by less than or equal to 0.25 microgram/ml of LY264826 and peptococci, peptostreptococci, and Fusobacterium were inhibited by less than 0.5 microgram/ml. Bacteroides species were LY284826 -resistant as were all Enterobacteriaceae, Flavobacterium, and Neisseria spp. Minimum bactericidal and inhibitory concentrations (MBCs and MICs) were within a dilution for S. aureus, S. pyogenes, and S. pneumoniae, but greater than or equal to 32-fold greater for enterococci.

摘要

LY264826是一种新的天然存在的糖肽,在浓度为1微克/毫升时可抑制90%的甲氧西林敏感和耐药金黄色葡萄球菌。LY264826对甲氧西林敏感和耐药的凝固酶阴性葡萄球菌具有相似的活性。化脓性链球菌的LY264826最低抑菌浓度(MIC90)为0.25微克/毫升,其活性比万古霉素高两倍,比替考拉宁低两倍。LY264826对肠球菌的活性比万古霉素高八倍,比替考拉宁高二倍。LY264826在浓度为0.25微克/毫升时可抑制肺炎链球菌,在浓度为0.5微克/毫升时可抑制单核细胞增生李斯特菌。梭菌被浓度小于或等于0.25微克/毫升的LY264826抑制,消化球菌、消化链球菌和梭杆菌被浓度小于0.5微克/毫升的LY264826抑制。拟杆菌属以及所有肠杆菌科细菌、黄杆菌属和奈瑟菌属对LY284826耐药。金黄色葡萄球菌、化脓性链球菌和肺炎链球菌的最低杀菌浓度和最低抑菌浓度(MBCs和MICs)在一个稀释度范围内,但肠球菌的MBCs和MICs比其高32倍或更高。

相似文献

1
In vitro activity of LY264826 compared to other glycopeptides and daptomycin.LY264826与其他糖肽类抗生素和达托霉素的体外活性比较。
Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):181-4. doi: 10.1016/0732-8893(91)90056-l.
2
In vitro activity of the new glycopeptide decaplanin.
Eur J Clin Microbiol Infect Dis. 1992 May;11(5):458-62. doi: 10.1007/BF01961864.
3
In vitro activity of LY146032 (daptomycin), a new peptolide.新型缩酚肽LY146032(达托霉素)的体外活性
Eur J Clin Microbiol. 1987 Feb;6(1):84-90. doi: 10.1007/BF02097208.
4
In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria.LY146032(达托霉素)对特定需氧菌的体外活性。
Eur J Clin Microbiol. 1987 Feb;6(1):91-6. doi: 10.1007/BF02097209.
5
In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.新型糖肽类抗生素LY264826对从癌症患者中分离出的革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1990 Nov;34(11):2137-41. doi: 10.1128/AAC.34.11.2137.
6
Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.源自LY264826的半合成糖肽类抗生素,对耐万古霉素肠球菌具有活性。
Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9. doi: 10.1128/AAC.40.9.2194.
7
Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.新型肽类抗生素短杆菌肽与万古霉素、替考拉宁和达托霉素的活性比较。
Antimicrob Agents Chemother. 1991 May;35(5):998-1000. doi: 10.1128/AAC.35.5.998.
8
In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.万古霉素、替考拉宁、达托霉素、雷莫拉宁、MDL 62873及其他药物对葡萄球菌、肠球菌和艰难梭菌的体外活性。
J Antimicrob Chemother. 1990 Nov;26(5):627-33. doi: 10.1093/jac/26.5.627.
9
In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.新型半合成糖肽LY333328的体外抗菌活性
Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165.
10
Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.新型脂肽类抗菌药物LY146032(达托霉素)的体外活性比较
Eur J Clin Microbiol. 1987 Feb;6(1):100-3. doi: 10.1007/BF02097211.

引用本文的文献

1
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Clin Microbiol Rev. 2000 Oct;13(4):686-707. doi: 10.1128/CMR.13.4.686.
2
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
3
Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.半合成糖肽类抗生素LY191145对耐万古霉素肠球菌及其他革兰氏阳性菌的抗菌活性。
Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. doi: 10.1128/AAC.39.11.2585.
4
Update on clinical significance of coagulase-negative staphylococci.凝固酶阴性葡萄球菌临床意义的最新进展
Clin Microbiol Rev. 1994 Jan;7(1):117-40. doi: 10.1128/CMR.7.1.117.